Overview

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ritter Pharmaceuticals, Inc.